Due to the sophistication of red cell compatibility testing, the majority of transfusion reactions are non-haemolytic in origin. This paper reviews the clinical presentation of these reactions, emphasising that blood transfusion reaction must always be considered in the differential diagnosis when a patient develops unexpected complications during his hospital stay. Fever, allergic reactions, respiratory distress, hypotension and jaundice may all be manifestations of a transfusion reaction.
best represent only a minimum. In the 600-bed city general hospital in which we work, 11,000 units of blood were administered in 1977-78. Over this period during which there were no acute haemolytic transfusion reactions, seventy-six non-haemolytic reactions comprising 34 cases of urticaria, 30 of fever, 6 of acute breathlessness, 4 of syncope and 2 of shock were notified. This paper reviews selected clinical aspects of non-haemolytic reactions following the transfusion of whole blood and packed red cells. For a more detailed discussion, the reader is referred to the papers of RudowskP and Baker, Moinichen and Nyhus. 2 
FEVER
Fever is the most common non-haemolytic transfusion reaction occurring in 3.6010 of transfusions in a recent study quoted by Mollison. 3 Earlier series 2 reported considerably higher figures but accurate data are notoriously difficult to obtain. Mild transient fever usually causes little or no concern to the patient and may not be noted unless the temperature is taken at very frequent intervals. The clinician is generally able to manage these reactions by simple measures and few are reported to the blood bank for further investigation. The temperature returns to normal usually within 8 hours following the cessation of the transfusion and the patient suffers no ill effects. Temperatures in excess of 38 QC are less common and are accompanied by restlessness and shivering commencing about half an hour to two hours after the start of the transfusion. If the transfusion continues, nausea, vomiting, facial flushing, headache, chest pain, back pain and a fall in blood pressure may occur. In debilitated and seriously ill patients such severe febrile reactions can be dangerous.
Before plastic disposable blood transfusion sets became generally used, febrile reactions were ascribed to the presence of pyrogens in the transfusion system. Pyrogens are high molecular weight products (usually lipopolysaccharides) of bacterial origin. In recent years increased appreciation 0 f the necessity for the careful preparation of distilled water and anticoagulant solutions and the replacement of rubber tubing and glass bottles by disposable plastic tubes and packs have resulted in virtual elimination of pyrogens from transfusion apparatus. Febrile reactions still occur however, and despite the availability of sophisticated immunological tests a significant number elude definition. Of 113 nonhaemolytic transfusion reactions investigated at the Edinburgh Royal Infirmary during 1974, a specific cause could be established in only 27 cases. 4 Notwithstanding the lack of laboratory confirmation, it is generally considered that the great majority of these reactions are immunologically mediated, the negative laboratory tests being due to the insensitivity of the test systems.
The most consistent laboratory abnormality found in the sera of patients with febrile transfusion reactions is the presence of alloantibodies directed against leucocyte antigens. The presumption that these antibodies are causally related is based on statistical data demonstrating a high frequency of the antibodies in such reactions. Support is provided by the experiments of Brittingham and Chaplin. 5 They produced febrile reactions by transfusing leucocyte-rich blood to five patients who had a history of previous febrile reactions and whose serum contained leucocyte alloantibodies. No reactions occurred when blood largely depleted of leucocytes was transfused.
Leucocyte alloantibodies are formed as the result of exposure to leucocytes from previous transfusions or pregnancy. Estimates of their prevalence vary widely depending on the serological techniques used. Early studies using the leucoagglutination test showed that 170/0 of multigravidae had demonstrable leucoagglutinin titres. 6 At least eight units of transfused blood are usually required to stimulate leucoagglutinin formation. 7 Among patients who have had febrile transfusion reactions, the prevalence of leucoagglutinins rises to between 50% and 70%.8 Many leucocyte alloantibodies detected in patients who have had febrile transfusion reactions are directed against HLA antigens and are best demonstrated by the lymphocyte cytotoxicity test.
However, it is probable that only HLA antibodies of high titre are capable of causing febrile transfusion reactions and most reactions due to leucocyte alloantibodies are caused by non-HLA granulocyte-specific antibodies, which are best detected by leucoagglutination. 3 The fever is considered to result from the release of intracellular pyrogen from injured granulocytes, although Perkins et al.1O have shown that the destruction of lymphocytes may also cause fever. As platelets share HLA antigens with leucocytes, it is not usually possible to delineate the role platelet destruction plays in the genesis of a febrile reaction associated with the presence of a clearly defined HLA antibody. Sensitization to platelet-specific antigens occurs and subsequent platelet injury or destruction may be responsible for mild fever in some instances.
Febrile reactions clearly related to the presence of antibodies to plasma constituents in the transfused blood are rare. Anti-IgA antibodies have been linked with the occurrence of allergic manifestations, which may be accompanied by fever. Reactions to other immunoglobulins and plasma constituents probably occur, but diagnostic tests are not widely available and reported cases are few. It should also be remembered that patients sustaining a haemolytic transfusion reaction 11 and those who have received infected blood Anaesthesia and Intensive Care, Vol. VIII, No. 2, May. 1980 may also develop a fever. These two entities are usually more dramatic than the previously described non-haemolytic transfusion reactions but occasionally fever is an early manifestation and the differential diagnosis may be difficult.
Febrile transfusion reactions due to leucocyte antibodies vary in severity depending on the antibody titre and the number of leucocytes transfused, and have no unique diagnostic features. Most are mild but at least one death has been reported. 12 Rarely a pulmonary syndrome develops.13 This is characterized by the sudden onset of fever, shaking chills and restlessness followed by breathlessness, cyanosis and a non-productive cough occurring after transfusion of 200-250 ml of blood. Widespread rales and rhonchi are heard over both lung fields but the jugular venous pressure is not elevated and there is no cardiomegaly. Chest x-ray shows extensive bilateral peri-hilar and basal pulmonary infiltrates. In some cases a peripheral eosinophilia has been reported. Acute symptoms usually last up to 12 hours and then gradually subside. The pulmonary infiltrates may persist for 48 hours. The reactions are generally associated with the presence of non-HLA leucoagglutinins in the plasma of the donor (who is usually a multiparous female) or less commonly in the recipient's plasma.
If a patient has a previous history of a mild febrile reaction, it may be possible to administer normal leucocyte-replete packed red cells provided the patient is observed carefully during transfusion and an anti-pyretic given. Thulstrup l4 found that 381170 of patients who had reacted to a previous blood transfusion tolerated a second transfusion without difficulty. If leucocyte alloantibodies are present and previous reactions have been severe, leucocyte depleted blood should be administeredY Buffy-coat poor blood may suffice if the antibody titre is low. In patients who suffer severe reactions, frozen-thawed washed red cells l6 are the most satisfactory preparation currently available and generally permit reaction-free transfusion.
Mild febrile reactions occurring during transfusion can usually be managed by reassurance, slowing the rate of transfusion and administering aspirin. More severe reactions require cessation of the transfusion. The Anaesthesia and Intensive Care. Vo!. VIII, No. 2, May, 1980 possibility of a haemolytic reaction or transfusion with infected blood should be excluded and general resuscitative measures undertaken.
ALLERGIC REACTIONS
Allergic reactions occur in about 3 % of all transfusions. 17 The most common manifestation is the sudden appearance of itchy areas of erythema or urticaria on the arms and trunk, often accompanied by fever. Less commonly the face or larynx are affected and an attack of asthma may develop. Rarely a severe anaphylactic reaction occurs shortly after the commencement of the transfusion, in which case there is flushing of the face and neck, nausea, sweating, chest and abdominal pain and breathlessness. The blood pressure falls, profound shock ensues and unless adequate resuscitation is promptly undertaken the patient may die.
Allergic reactions are due in some instances to allo-antibodies in the patient's serum which react with IgA in the transfused blood. The severe anaphylactic reactions referred to above are most frequently seen in subjects who lack IgA in their serum. Vyas et al. 18 tested over 70,000 blood donors and found that IgA was completely absent in the serum of 83. Of these 83 subjects, 13 had high titre class-specific anti-IgA antibodies which were IgG in type, bound complement and reacted with all IgA idiotypes. The majority denied previous pregnancies and had never been transfused. Transfusion of blood or blood products containing IgA to sensitised persons inevitably results in a severe anaphylactic reaction, probably due to the generation of the biologically active complement components, C3a and C5a.
The relationship between mild allergic reactions and anti-IgA antibodies in the recipient's serum is less clear. Antibodies of limited specificity, directed against only part of the IgA molecule, occur in persons with normal IgA levels, most of whom have either been pregnant or have received IgA containing blood or blood products in the past. Koistinen and Leikola 19 investigated 158 mild allergic reactions and found that 6.3% of affected patients had low titre anti-IgA antibodies of limited specificity. Similar antibodies have also been found in subjects who have been transfused with IgA containing blood products without incident and a causal relationship between the antibodies and mild allergic reactions remains unproven. 20 Allo-antibodies against other immunoglobulins may be found in multiparous females and multi-transfused subjects. Anti-Gm antibodies react with determinants on IgG heavy chains and anti-In V antibodies with determinants on light chains. Anti-IgM antibodies are frequently found in transfused thalassaemic patients. Although it is quite conceivable that such antibodies may be related to some allergic or febrile episodes following blood transfusions, cases with clearly documented and convincing laboratory and clinical data are scarce.
As many patients who experience allergic reactions following transfusion have a previous history of similar reactions, careful questioning of the patient for a history of asthma or allergic skin conditions should precede any transfusion. If previous transfusion reactions have been mild, an oral dose of antihistamine should be given 15 minutes before the transfusion is commenced. If a history of severe reactions is obtained, thoroughly washed red cells or frozen-thawed red cells are usually sufficiently free of IgA to permit safe transfusion. Blood from an IgA deficient person is a more satisfactory alternative if available, and may be essential in some patients. A number of blood banks now maintain a register of IgA deficient persons. 21 The management of an allergic reaction occurring during a transfusion depends on the degree of severity. If the reaction is limited to only a few urticarial wheals the transfusion is slowed and subcutaneous adrenaline and antihistamines are administered. With more severe reactions the transfusion must be stopped, hydrocortisone and vasopressors given intravenously and general resuscitative measures commenced.
PULMONARY CONGESTION AND OEDEMA
Cardio-respiratory symptoms during and following blood transfusion are generally due to acute hypervolaemia and cardiac failure. Less commonly immunological reactions to leucocytes, platelets or plasma proteins cause severe dyspnoea and radiological changes which may present diagnostic difficulties.
The elderly, many of whom have coronary atherosclerosis and myocardial impairment are particularly prone to develop circulatory overload during transfusion. A large amount of blood given rapidly to a young healthy normovolaemic subject causes an acute increase in blood volume. The jugular venous pressure rises and pulmonary vital capacity is diminished. Regulatory mechanisms rapidly compensate for the circulatory disturbances, but such mechanisms are impaired in elderly patients with suboptimal cardiac and pulmonary function.
The onset of cardiac failure with pulmonary congestion during a blood transfusion is usually easily recognised. The patient becomes restless, complains of chest tightness and headache and breathlessness develops, often with a dry cough. The jugular venous pressure rises, crepitations develop at the lung bases and severe pulmonary oedema supervenes. This clinical picture is no longer commonly seen in medical practice due to increased awareness of the dangers of transfusion in elderly people and the availability of concentrated red cells and potent diuretics. As always prevention is better than cure, and it is essential to ensure that the elderly anaemic patient about to receive a blood transfusion is in the best possible condition. If time allows, the patient should be digitalized and a diuretic given immediately before the transfusion. Frusemide 20 mg intravenously is probably the most satisfactory preparation available. While the transfusion is in progress, the patient should be propped up in bed, given oxygen and kept warm. Concentrated red cells are mandatory. They should be transfused slowly, each unit over a period of 4-6 hours. Careful observation of the patient with monitoring of the jugular venous pressure is essential and for this reason it is unwise to transfuse an elderly patient at night. Placement of a central venous catheter may be required in some cases. If signs of pulmonary congestion develop, the transfusion should be stopped and additional diuretics given. If rapid improvement does not occur venesection should be considered. Partial exchange transfusion is useful in desperate situations, but in the authors' experience is rarely required in current medical practice. SEPTICAEMIA The steps involved in the acquisition, storage and administration of blood provide several opportunities for bacteria to gain access to the system. Nevertheless, microbiological studies of blood units have indicated a very low contamination rate and practical experience confirms that septicaemia following transfusion is a rare event.
Braude et al. 22 found that 2.2% of blood units examined after 24 hours storage at 4°C were contaminated, the majority with nonpathogenic staphylococci. Positive cultures are rarely obtained from units stored longer than 24 hours at 4°C as any contaminants are killed by the bacteriostatic activity of blood. An occasional problem is presented by psychrophilic organisms, primarily pseudomonads, coliforms and achromobacters which are capable of growth at refrigerator temperature and produce endotoxin. Transfusion of even a small amount of blood heavily infected with these organisms can result in endotoxaemia with high fever, profound shock and a high mortality rate. Growth and endotoxin production are greatly accelerated at room temperature and most blood banks have strict rules prohibiting removal of blood units from low temperature storage for more than half an hour for any purpose except actual administration to the patient.
Infected catheter tips and intravenous sites undoubtedly constitute a more frequent source of transfusion-related septicaemia than infected blood units. In order to prevent infection it is necessary to attend to the proper care of catheters and to change intravenous sites frequently.
ALTERED RETICULOENDOTHELIAL FUNCTION
The important role of the reticuloendothelial system in the clearance from the circulation of bacteria, activated coagulation factors and antigen-antibody complexes has been the subject of much recent interest. Recent observations have suggested that blood transfusion temporarily blocks reticuloendothelial function 23 with subsequent impairment of body defence. Important in vitro observations by Keown and Descamps24 have linked red cell phagocytosis by mononuclear cells to depression of response to antigen of Anaesthesia and Intensive Care, Vol. VIII. No. 2, May, 1980 bystander lymphocytes. An identical series of events in vivo may provide one explanation for the beneficial effect of blood transfusion on the survival of renal allografts. 25
JAUNDICE FOLLOWING TRANSFUSION
In the immediate post-transfusion period, the onset of jaundice generally indicates the presence of an acute haemolytic transfusion reaction. In spite of highly sensitive pretransfusion compatibility tests and "fail-safe" precautions against clerical errors in the laboratory and at the bedside haemolytic reactions still continue to occur with depressing frequency. Most are due to ABO incompatibility between donor and recipient and Mollison,9 in summarising two recent analyses from large blood banks, has estimated that ABO incompatible blood is transfused to approximately 1 in 5000 recipients with a mortality rate of around 10070. A rise in serum bilirubin which reaches its maximum 3-6 hours after the haemolytic episode is a consistent finding in nearly all haemolytic transfusion reactions although clinical jaundice may not be apparent in mild cases.
In the third and fourth week following transfusion, jaundice is usually due to the occurrence of a delayed haemolytic transfusion reaction. 26 The onset is usually more insidious than in acute transfusion reactions and fever and anaemia are the main clinical manifestations. Hyperbilirubinaemia occurs in nearly all cases and in some jaundice may be the only notable clinical abnormality. In both immediate and delayed haemolytic transfusion reactions the characteristic serological findings and the biochemical pattern of mild unconjugated hyperbilirubinaemia with normal serum aspartate transaminase and alkaline phosphatase levels and absence of bile in the urine confirm the diagnosis.
Jaundice after the fourth week following transfusion is generally due to post-transfusion hepatitis 27 which remains the main hazard of blood transfusion with a mortality rate of around 10%. The elimination from blood donor panels of nearly all donors carrying ~he hepatitis B virus (HBV) by the use of thIrd generation serological screening tests for the hepatitis B surface antigen (HB,Ag) has reduced by 5 to 10 fold the prevalence and severity of type B viral hepatitis among transfusion recipients. However, although post-transfusion hepatitis due to the hepatitis B virus has become a relatively rare disease, the overall reduction in post-transfusion hepatitis has been only of the order of 25070, which is considerably less than was originally anticipated. 28 Recent studies in the United States 29 have shown that up to 90% of patients with post-transfusion hepatitis have no serological evidence of infection with hepatitis A virus, hepatitis B virus or any other infectious agent known to cause hepatitis. The current presumption that these cases of seronegative hepatitis, currently referred to as non-A, non-B hepatitis 30 are due to infection with an unnamed virus or viruses has recently been strengthened by experiments in which serum from affected patients has been inoculated into chimpanzees who have subsequently developed clinical and biochemical stigmata of acute hepatitis. 31 The characteristic clinical picture and biochemical profile of hepatocellular jaundice occurring in hepatitis B are well known. The incubation period generally ranges from 30-150 days. Occasional patients in whom jaundice has been first noted 14 days after transfusion have been described and the diagnosis must be seriously considered even in this early period. The incubation period of non-A, non-B hepatitis is slightly shorter than that of hepatitis B and the disorder is generally milder. However, the incidence of progression to chronic liver disease is probably higher. In all other respects, the clinical pictures are identical.
It is important to characterise serologically cases of post-transfusion hepatitis for epidemiological purposes. HBsAg is found in the serum of nearly all patients with hepatitis B when jaundice becomes apparent, and Krugman et al. 32 have recently shown that the antigen can be detected as early as six days after exposure to the virus. In occasional cases HBsAg disappears rapidly following the onset of jaundice but it usually persists into early convalescence. Antibody to hepatitis B core antigen (anti-HBc) also appears in the initial phase of the illness and is present in convalescence and beyond. Its detection may be useful diagnostically in those patients who become HBsAg negative early. Serological markers for non-A, non-B hepatitis are not yet available, and the diagnosis at present is made by exclusion.
In Australia prevalence rates for posttransfusion hepatitis are not known with certainty but as only 0.1 % of blood donors are HBsAg positive 33 one would expect hepatitis B at least to be less common than in the United States where positive donors are generally more frequent. The National Blood Transfusion Committee of the Australian Red Cross has initiated a study of post-transfusion hepatitis which should yield more accurate data in the near future. The presence of non-A, non-B hepatitis in the Australian community (particularly amongst drug addicts) has been confirmed by Gust 34 and early results from the Red Cross study suggest that a significant number of cases of post-transfusion hepatitis are of this type.
In contemporary hospital practice, blood transfusions are frequently given in association with major operative procedures and to severely ill patients with pre-existing hepatic dysfunctionY Elevated bilirubin levels and clinical jaundice may occur in these complex clinical settings without serological evidence of an overt haemolytic transfusion reaction. It is often difficult to dissect accurately the aetiology of this type of jaundice as a variety of factors capable of exerting a deleterious effect on liver cell function are inevitably present. These include hypoxaemia, decreased vascular perfusion, the administration of anaesthetic and other drugs and generalised sepsis. A 500 ml transfusion liberates 7.5 g of haemoglobin which in turn results in the production of about 250 mg of bilirubin. The functionally normal liver is able to dispose of this extra bile pigment load with ease but if hepatic impairment is present, there may be decreased excretion of conjugated bilirubin as well as impaired uptake and conjugation. As a result unconjugated hyperbilirubinaemia and varying degrees of conjugated hyperbilirubinaemia occur. When defective excretion is the predominant lesion, the clinical picture of benign postoperative intrahepatic cholestasis 36 is seen.
